Navigation Links
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Date:5/11/2009

RM-1 trial as an oral late breaker at the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. This is the first study to investigate the activity of a combination of two oral antiviral molecules to treat HCV in the absence of interferon. The study is investigating the combination of Pharmasset's R7128, a nucleoside inhibitor, with InterMune's R7227, a protease inhibitor;
  • On April 24, 2009, Pharmasset announced that its development partner, Roche, had initiated dosing of patients in the phase 2b trial of R7128 in combination with the standard of care in genotype 1 and 4 HCV infected patients. The start of the trial triggered a $10.0 million milestone payment to Pharmasset that is expected to be received in the quarter ending June 30, 2009;
  • On April 20, 2009, Pharmasset announced that it had voluntarily halted its phase 3 registration studies of clevudine for the treatment of chronic hepatitis B infection;
  • On March 31, 2009, Pharmasset announced the dosing of the first healthy volunteer in the phase 1 trial with PSI-7851, a second generation nucleotide inhibitor of HCV.

  • "Our HCV pipeline continues to make solid progress," stated Schaefer Price, President and Chief Executive Officer. "In April, we announced exciting data from the INFORM-1 trial at EASL and the initiation of the phase 2b trial with R7128. We are now able to increase our focus on further strengthening our portfolio of HCV nucleos(t)ides with the decision to halt registration studies with clevudine. We look forward to providing the first antiviral data on PSI-7851 in the second half of 2009."

    Calendar Year 2009 Anticipated Milestones:

    • Announce selection of candidate(s) from our purine series of nucleos(t)ide analog for HCV in second half of 2009;
    • Provide update on safety from first 100 patients in t
      '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
    3. Pharmasset Accesses up to $30 Million of Working Capital
    4. Pharmasset to Present at Three Investor Conferences in November 2007
    5. Pharmasset Appoints Michael Rogers as Chief Development Officer
    6. Pharmasset Reports Fiscal Year End 2007 Financial Results
    7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
    8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
    9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
    10. Pharmasset Appoints Herbert J. Conrad as a Director
    11. Pharmasset Receives $10 Million of Working Capital
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
    (Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
    (Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
    (Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
    Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
    ... to use anti-theft software Rockwell signs agreement ... for data imaging Wisconsin bankers ... of Wisconsin will be the first state banking association ... announced on Wednesday at BAI's Retail Delivery Conference and Expo ...
    ... place inside the Monona Terrace. (Jason Stitt/WTN) Angel ... of Wisconsins continually evolving technology culture at the ... and Wednesday at the Monona Terrace. , ,Biotech companies ... panels studied the future of the states industry. , ...
    ... Wisconsin Institute for Discovery It was inevitable that ... interdisciplinary research center on the UW-Madison campus would be ... a $3 billion, 10-year initiative to fund human embryonic ... research is a sizable part of what will happen ...
    Cached Biology Technology:Life-sciences conference showcases capital ideas of Wisconsin 2Life-sciences conference showcases capital ideas of Wisconsin 3Doyles proposal is about more than keeping pace with California 2Doyles proposal is about more than keeping pace with California 3
    (Date:7/11/2014)... Social animals often develop relationships with other group members ... In wild chacma baboons the strategy for grooming activities ... are just published in the scientific journal Biology ... of baboons is not practiced without ulterior motives. To ... for the individual, while grooming another individual can provide ...
    (Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
    (Date:7/11/2014)... marginal division of the striatum is also involved ... degree of substance P in the striatal marginal ... and his team, College of Biophotonics, South China ... substance P receptor, neurokinin 1 was highly expressed ... normal rats. Unilateral or bilateral injection of an ...
    Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
    ... - an antibacterial chemical found in toothpaste and other ... allergy development in children. This comes from the Norwegian ... Institute of Public Health is involved. Similar results are ... in use for decades, but was recently associated with ...
    ... is when a horse shakes or jerks its head ... similarities between facial pain syndromes in people, most notably ... has been made towards both diagnosing and treating the ... unknown and further research is needed. ...
    ... in combination with other measures, could significantly improve numbers ... a fish modelling study has found., Scientists working at ... Secretariat of the Pacific Community (SPC, Noumea, New Caledonia) ... that a network of marine zones in the Pacific ...
    Cached Biology News:Triclosan in cosmetics and personal care products can increase allergy risk 2Study investigates headshaking in horses 2Pacific fishing zones -- lifeline for overfished tuna? 2
    ... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
    Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
    Request Info...
    Myt 1 (N-17)...
    Biology Products: